Dizhe Pharmaceutical announced that the results of the Phase II clinical study of biritinib as a single drug to treat recurrent/refractory diffuse large B-cell lymphoma were officially published in the “Journal of Hematologic Oncology”; the study showed that the overall objective remission rate reached 47.6%, the complete remission rate was 31.0%, and no drug-related major bleeding or atrial fibrillation events were reported.

Dizhe Pharmaceutical announced that the results of the Phase II clinical study of biritinib as a single drug to treat recurrent/refractory diffuse large B-cell lymphoma were officially published in the “Journal of Hematologic Oncology”; the study showed that the overall objective remission rate reached 47.6%, the complete remission rate was 31.0%, and no drug-related major bleeding or atrial fibrillation events were reported.